Congenital acute myeloid leukemia (AML), and especially AML-M6 is a rare disease with a poor prognosis. Moreover, reports of treatment outcome of congenital AML-M6 in premature infants are not available. We report the first treated case of congenital AML-M6 in a premature girl, who received a full AML protocol. She presented with blueberry-muffin spots, anemia, high white blood cell count, and serious cardiopulmonary distress. Peripheral blood smears showed AML-M6 blasts. After treatment with a sequential low-dose cytarabine after birth and full-dose AML treatment according to the MRC-12 protocol at the age of 2 months, she now is in continuous complete remission for 4 years. Copyright

AML-M6, Cardiomyopathy, Congenital leukemia, Prematurity
dx.doi.org/10.1097/MPH.0b013e3181b38b6c, hdl.handle.net/1765/24733
Journal of Pediatric Hematology / Oncology
Erasmus MC: University Medical Center Rotterdam

van Dongen, J.C.A, Dalinghaus, M, Kroon, A.A, de Vries, A.C.H, & van den Heuvel-Eibrink, M.M. (2009). Successful treatment of congenital acute myeloid leukemia (AML-M6) in a premature infant. Journal of Pediatric Hematology / Oncology, 31(11), 853–854. doi:10.1097/MPH.0b013e3181b38b6c